Bebangco, Elliesha Kate A.
HRN: 10-44-55 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/17/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/17/2022
10/24/2022
IVTT
210mg
Q8h
Intestinal Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes